Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

INTRODUCTION: Semaglutide, a new treatment option approved for the treatment of patients with type 2 diabetes mellitus, is a glucagon-like peptide-1 receptor agonist to be injected subcutaneously once weekly. This analysis used a population pharmacokinetic model of semaglutide to identify clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsson Petri, Kristin Cecilie, Ingwersen, Steen Hvass, Flint, Anne, Zacho, Jeppe, Overgaard, Rune Viig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064581/
https://www.ncbi.nlm.nih.gov/pubmed/29907893
http://dx.doi.org/10.1007/s13300-018-0458-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064581/
https://www.ncbi.nlm.nih.gov/pubmed/29907893
http://dx.doi.org/10.1007/s13300-018-0458-5

Ejemplares similares